Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
COVID-19
COVID-19 Partnering Event
COVID-19 Daily Update
COVID-19 EventAnalyzer
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
EvaluatePharma Vision
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
English
日本語
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Ranbaxy Laboratories
October 15, 2014
Shabbvie marks difference between great and exceptional deal quarter
June 27, 2014
Delayed Diovan generic emerges – Valcyte and Nexium next?
May 16, 2014
Novartis settles Gleevec as other patent fights continue
April 07, 2014
Daiichi’s ill-timed Indian foray ends in minority Sunbaxy stake
January 07, 2014
Biotech bull run leaves few big cap drug stocks down in 2013
October 22, 2013
Clock ticks for Ranbaxy as Novartis continues to reap Diovan revenues
October 01, 2013
Surging US drives strong drug stock performances at nine month stage
September 02, 2013
ESC – Daiichi joins the US-EU blood-thinning race with positive Lixiana data
July 03, 2013
Biotech continues to reward investors in first half
April 04, 2013
Biotech consolidates its dominance in the first quarter
September 28, 2012
Supreme Court could be next up in "pay for delay" saga
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 20, 2020
Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review
December 17, 2019
Evaluate Vantage 2020 Preview
Editor's Picks
April 03, 2020
The long path to an effective coronavirus vaccine
March 18, 2020
A Covid-19 treatment plan slowly emerges
March 31, 2020
Amarin falls at obvious hurdle
March 20, 2020
Clinical trial delays become reality as Covid-19 risk spreads
March 10, 2020
Few groups have developed Covid-19 diagnostics – but this will change
